Acute heart failure (AHF) is defined as rapid change in heart failure signs and symptoms resulting in the need for urgent therapy. The syndrome is complex and has multiple etiologies. Most of the therapies for acute heart failure are mainly addressing the symptomatic relief of fluid overload and only very few effective treatments are available for AHF that improves clinical outcomes.

There are three groups of patients with acute heart failure on the basis of systolic blood pressure (SBP) at the time of presentation.

1. Patients presenting with hypertension and have preserved systolic function. Their in-hospital mortality is approximately 2%.

2. Patients presenting with normal blood pressure tend to have a lower left ventricular ejection fraction (LVEF) and signs and symptoms of pulmonary/systemic congestion (edema) before and at the time of presentation. The in-hospital mortality is approximately 3%.

3. Patients presenting with low blood pressure generally have a low LVEF, and have a previous history of HF. In-hospital mortality is approximately 7%.

These three patient groups not only differ prognostically but also require appropriately tailored pharmacologic treatments. Most patients with acute heart failure with high or normal blood pressure at the time of admission present with pulmonary or systemic congestion and relatively normal cardiac output, and their early management is mainly directed at correcting high LV filling pressure and after load. Conversely, in patients hospitalized with acute heart failure who present with low SBP, first-line therapies are targeted at low cardiac output in addition to congestion. Most of the drugs commonly used for the treatment of acute heart failure having well-known limitations and have been associated with an early increase in the risk of death. Therefore, there is an immense need for new drugs for the acute heart failure patients presenting with congestion or low cardiac output that can safely improve hemodynamics, symptoms and possibly long-term survival. The aim of this paper is therefore to review recent advances on emerging drugs in acute heart failure and to summarize evidence of clinical benefit.

New Drugs for Acute Heart Failure

MOHAMMAD SALMAN1, SYED ALI AHSAN2, MANZOOR MAHMOOD2, MD. KHAIRUL ANAM2, SHAHED MOHAMMAD ANWAR3, ROKSANA AFROSE4, MD. ABU SIDDIQUE2, MD. ASHRAF UDDIN SULTAN2, FAZLUR RAHMAN2

1Department of Cardiology, Anwer Khan Modern Medical College, Dhanmondi, Dhaka, 2Department of Cardiology, Bangabandhu Sheikh Mujib Medical University, Dhaka, 3University of Science and Technology, Chittagong, 4Chittagong Ma O Shishu and General Hospital, Chittagong.

Address for Correspondence: Dr. Md. Salman, Department of Cardiology, Anwar Khan Modern Medical College, Dhaka, E-mail: drmdsalman@gmail.com

Abstract

Acute heart failure is a major health problem responsible for several million hospitalizations worldwide each year. Standard therapy has not changed for long time and includes diuretics and variable use of vasodilators or inotropes. Recently Nesiritide and Levosimendan are two drugs for the treatment of acute heart failure which have been approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMEA), respectively. There was little concern that Nesiritide can worsen the renal failure but recent trials had abolished this concern.

Key Words: Acute heart failure, Nesiritide, Levosimendan.
safety and efficacy of these agents have recently been questioned and Nesiritide has not been approved by EMEA and Levosimendan has not been approved by FDA. Although previous studies demonstrated that these new therapies improve hemodynamic parameters, recent meta-analyses and randomized trials suggest that they may increase or have comparable impact on long-term mortality, compared to conventional drugs.

Nesiritide

Nesiritide is a recombinant form of human brain natriuretic peptide (BNP) that exerts vasodilatory effects on arterial, venous, and coronary vessels, leading to increased cardiac output. Studies of Nesiritide in the treatment of acute heart failure have documented beneficial effects on hemodynamics (reductions in PCWP and systemic vascular resistance and increases in cardiac output) and symptoms.\(^9,10\) The Vasodilatation in the Management of Acute Congestive Heart Failure (VMAC) trial was a multicenter, randomized, double-blind, controlled trial designed to compare the hemodynamic and clinical effects and safety of intravenous Nesiritide and intravenous Nitroglycerin added to standard care in patients hospitalized for dyspnea at rest due to acute heart failure.\(^11\) Patients were randomized to receive Nesiritide, Nitroglycerin or placebo for 3 hours. After 3 hours, Nesiritide reduced PCWP to a significantly greater degree than did nitroglycerin or placebo. Nesiritide significantly improved dyspnea compared with placebo but resulted in no significantly different improvement in dyspnea compared with nitroglycerin. After 24 hours, the mean reduction in PCWP was significantly greater in the Nesiritide group than in the nitroglycerin group, but there was no significant difference in dyspnea between the two groups. Adverse events (most commonly headache) occurred significantly less frequently with Nesiritide than with Nitroglycerin. There was no significant difference in 6-month mortality rates in the Nesiritide group compared with the Nitroglycerin group.

The safety and efficacy of Nesiritide has been questioned recently.\(^12\) The main concern is about the possible adverse effects of Nesiritide therapy on renal function\(^13\) and short-term mortality, in comparison with standard diuretic and vasodilator therapies.\(^14,15\) The BNP-CARDS (B-Type Natriuretic Peptide in Cardiorenal Decompensation Syndrome) trial randomized 75 consecutive patients with acute heart failure and baseline renal dysfunction to receive Nesiritide (0.01 ìg/kg/min with or without a 2-ìg/kg bolus) or placebo (5% dextrose in water) for 48 h in addition to usual care.\(^16\) There were no significant differences in the increase in serum creatinine by 20% and change in serum creatinine between the two groups. In addition, there were no significant differences in the secondary end points of change in weight, intravenous frusemide use, discontinuation of the infusion due to hypotension, or 30-day death or hospital readmission.\(^16\) A possible explanation for the disparate findings between this and previous studies is the use of a bolus dose. Probably Nesiritide has some effect on glomerular filtration rate due to the significant hypotension occurring with the bolus dose, possibly accounting for some of the worsened renal function seen in other retrospective analyses. Another possible difference between the results of this trial and previous observations are the timing of the Nesiritide infusion initiation and the dose of infusion used. Data from the second Follow-Up Serial Infusions of Nesiritide in Advanced Heart Failure (FUSION-2) trial have been presented.\(^17\) The trial randomized 911 patients to receive Nesiritide as a 2-ìg/kg bolus followed by a 0.01-ìg/kg/min infusion for 4 to 6 h or a placebo regimen, once or twice a week for 12 weeks. Inclusion in the trial required being in NYHA class III or IV with an LVEF d’40% and a history of at least two prior hospitalizations for acute heart failure within the past year. Patients in NYHA class III were only recruited if their creatinine clearance was e’60 mL/min. No outpatient IV inotropic or vasodilator therapy was allowed during the study. At the end of the study, there were no significant differences in rates of the primary end point of all cause mortality or cardiovascular or cardio renal hospitalization or in rates of its individual component events.\(^17\) The Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure (ASCEND-HF) trial is randomized, double-blind, placebo-controlled study. The following conclusions came from this study. Nesiritide did not reduce the rate of recurrent heart failure hospitalization or death at 30 days. Nesiritide reduced dyspnea to a modest degree, consistent with previous findings but did not meet pre-specified protocol criteria for statistical significance at 6 and 24 hours. Nesiritide did not affect 30-day all cause mortality nor did it worsen renal function as had been suggested by prior meta-analyses of smaller studies. Nesiritide can now be considered as a safe therapy in patients with acute heart failure.

Lemosimendan

Calcium sensitizing agents are a newer class of positive inotropic drugs that include levosimendan, pimobendan, senazodan, EMD-53998, and its enantiomer, ED-57033.\(^18\) These drugs exert a dose-dependent calcium sensitizing
mechanical enhancement on the failing heart via various type of biochemical mechanisms, including the enhancement of troponin-C affinity for calcium, the direct stabilization of the calcium-induced conformation of troponin-C, or the action distal to the troponin-C molecule.\(^{18}\) However, some molecules such as pimobendan, EMD- 53398, senazodan and possibly levosimendan may act as phosphodiesterase inhibitors at therapeutic doses, causing a deleterious increase of intracellular cyclic AMP. This effect seems to be an essential limitation for the use of these drugs clinically.\(^{18}\) Levosimendan is the most studied calcium sensitizer and has recently been introduced in many countries for the treatment of acute heart failure. Levosimendan acts via two complementary mechanisms.\(^{19}\) It enhances contractility by improving cardiac myofilament response to intracellular calcium and it reduces the cardiac workload by opening ATP-dependent potassium channels for dilation of blood vessels.\(^{19}\) Indeed levosimendan-induced decrease in right and left ventricular after load may be beneficial in failing hearts.\(^{19,20}\) Furthermore, levosimendan differs from classic inotropes because of its ability to improve myocardial efficiency without increasing myocardial oxygen demand, its effects on coronary blood flow, and its lack of negative lusitropic effects.\(^{19,20}\) Data from several trials suggest that levosimendan appears to improve hemodynamics, symptoms and neurohormonal response\(^{21-23}\) in acute heart failure and to possibly prolong survival in some subsets of patients. For instance, in the Randomized Study on Safety and Effectiveness of Levosimendan in Patients with Left Ventricular Failure Due to an Acute Myocardial Infarct (RUSSLAN) study\(^{24}\) and in the Levosimendan Infusion Versus Dobutamine (LIDO) study,\(^{25}\) levosimendan was associated with hemodynamic improvements and in secondary with a lower risk of death compared to Dobutamine and in post-MI or low-output heart failure patients. The recent REVIVE-1 and -2 (Randomized Evaluations of Levosimendan) and SURVIVE (Survival of Patients with Acute Heart Failure in Need of Intravenous Inotropic Support) trials showed that levosimendan was superior to placebo or Dobutamine, respectively, in producing clinical improvement and beneficial neurohormonal modulation (as expressed by the reduction in plasma BNP) in patients with acute heart failure.\(^{26-28}\) However, levosimendan failed to lead in a reduction of in hospital and 6-month mortality compared with Dobutamine (SURVIVE: primary end point) in these patients. More specifically, in the REVIVE-2 study,\(^{26}\) 90-day all-cause mortality was 15.1% in the levosimendan group and 11.6% among placebo-treated patients (p=0.210); this numerical increase in deaths in the levosimendan group was associated with the higher incidence of hypotensive episodes than in the placebo group. The SURVIVE trial\(^{28}\) randomized 1327 patients with acute diastolic heart failure and a left ventricular ejection fraction of 30% or less, who required intravenous inotropic therapy because of insufficient response to intravenous diuretics or vasodilators. All patients received standard treatment and were randomized to the addition of either a 12-ìg/kg bolus of levosimendan followed by a stepped dose regimen of 0.1– 0.2 ìg/kg/min infusion for a maximum of 24 hours or Dobutamine at a dose of at least 5 ìg/kg/min for at least 24 hours. The primary end point in the SURVIVE trial (all-cause mortality at 6 months) showed similar results for both levosimendan and Dobutamine (26.2% and 27.9%, respectively; p=0.401). Interestingly SURVIVE shows that levosimendan induced a much greater decrease in BNP compared to Dobutamine, over the first week of treatment.\(^{28}\) Levosimendan is currently in clinical use in several countries (excluding US) and is indicated in patients with symptomatic low cardiac output HF secondary to cardiac systolic dysfunction without severe hypotension.\(^{29}\) Further studies are clearly needed in order to identify proper dosages and timing of infusion, and the subset of patients who may benefit more from this drug.

**Conclusion**

No new agent has demonstrated a clear benefit in terms of long-term clinical outcomes compared to conventional therapies. Since recent studies demonstrated that early management may influence long-term outcomes, a major challenge in acute heart failure trials remains the development of appropriate time for initiation of therapy and end points for evaluating the efficacy of these new pharmacologic therapies.

**References**


